Sidal expects to increase the volume of its exports by 10% to African countries

The President and Director General of the Sidal Group, Wassim Koueidry, revealed that by 2025, Sidal expects to increase the volume of its exports by 10 percent, especially to African countries.

During his presentation to the Health, Labor and Vocational Training Committee of the National People’s Assembly, Qouidari explained that the Saidal Complex is a partner with many major international and regional laboratories, and these partnerships aim to expand the range of products into new therapeutic areas, especially anti-cancer medicines and medicines derived from biotechnology.

Kouedri added that the Sidal complex is the national leader in the generic pharmaceutical industry and is considered the first Algerian pharmaceutical laboratory to produce generic medicines in Algeria, noting that Sidal constitutes a tool for establishing the national pharmaceutical policy and contributing decisively to reducing the drug import bill, regulating the market, and developing the national pharmaceutical industry, as well as achieving Health security.

The same official indicated that the complex consists of 08 production units, 03 distribution centers, two support structures, and a research and development center whose mission is to provide technological support to the production units and develop new products, which is a new structure, as well as a center for bioequivalence.

The same official noted that the turnover increased from 14.6 billion dinars in 2022 to more than 18.5 billion dinars in 2023, and the level of production increased from 114 million units in 2022 to more than 128 million in 2023.

The same official stressed that the complex aspires to enrich its product list, provide innovative treatments for Algerian patients, ensure health security, and reduce the import bill while exporting abroad.

The director of Sidal added that the complex’s strategy is based on the production of raw materials with the aim of increasing the rate of integration, especially insulin crystals, antibiotics, in addition to paracetamol, as well as developing a range of Sidal products such as vaccines, eye drops and soft capsules.

For his part, the Chairman of the Health Committee congratulated the President and Director General of the complex and all those in charge of the sector on the occasion of laying the foundation stone for the completion of a new production unit for Sidal specializing in the production of ophthalmic and veterinary medicines, which ceremony took place during the visit of the Minister of the Sector, Ali Aoun, to the state of Mostaganem, and stressed that it will contribute to Creating a significant number of job positions.

During the discussion, the representatives expressed many concerns, centered around the reason for the delay in the research and development center in the city of Sidi Abdellah, as well as the biointegration center in the municipality of Hussein Dey, in entering into service, the possibility of attracting specialized competencies in the field of biology, and the extent of the possibility of increasing the production of medicines for eye diseases, especially In partnership with the Cubans.

The representatives also touched on the necessity of expanding the production network, opening branches of the Saidal complex in many states of the country and enabling Saidal to compete in foreign markets, and Saidal’s policy in research and the incentive measures taken regarding the complex’s frameworks and the projects currently in the field of marketing.

The representatives also asked about the fate of the remaining quantities of the anti-Covid vaccine produced by the complex, and whether Sidal produces a sufficient quantity of the drug directed to amyophobia patients.